Company: ENTXW
Filing Date: 2025-06-06
Form Type: 424B3
Source: 0001178913-25-002133
Chunk: 12

Company: Entera Bio Ltd.
Filing Date: 2025-06-06
Form: 424B3
Chunk 12
---
 concern absent access to sources of liquidity; |

| • | Our ability to raise additional funds or consummate strategic partnerships to offset additional required capital to pursue our business objectives, which may not be available on acceptable terms or at all. A failure to obtain this 
 additional capital when needed, or failure to consummate strategic partnerships, could delay, limit or reduce our product development, and other operations;                                                                           |

S-7

| • | Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial 
 success;                                                                                                                                                                                                                                   |

| • | The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and third-party payors establish adequate coverage and reimbursement levels and pricing 
 policies;                                                                                                                                                                                                                            |

| • | Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue; |

| • | If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products similar 
 or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected;                                                                                                                         |

| • | Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain; |

| • | Our reliance on third parties to conduct our clinical trials and on third-party suppliers to supply or produce our product candidates; |

| • | Our interpretation of FDA feedback and guidance and how such guidance may impact our clinical development plan; |

| • | Our ability to use and expand our drug delivery technology (“N-Tab™”) to additional product candidates; |

| • | Our operation as a development stage company with limited operating history and a history of operating losses and our ability to fund our operations going forward; |

| • | Our competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories we pursue; |

| • | Our ability to establish and maintain development and commercialization collaborations; |

| • | Our ability to manufacture and supply enough material to support our clinical trials and any potential future commercial requirements;